

Liisa M Pelttari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1481355/publications.pdf>

Version: 2024-02-01

33
papers

1,918
citations

361413

20
h-index

395702

33
g-index

33
all docs

33
docs citations

33
times ranked

4572
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
2	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
3	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	3.2	174
4	Exome sequencing identifies <i>FANCM</i> as a susceptibility gene for triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15172-15177.	7.1	162
5	<i>RAD51C</i> is a susceptibility gene for ovarian cancer. <i>Human Molecular Genetics</i> , 2011, 20, 3278-3288.	2.9	124
6	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
7	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	6.3	106
8	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	1.9	71
9	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
10	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.	12.8	63
11	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	2.5	44
12	A Finnish founder mutation in <i>RAD51D</i> : analysis in breast, ovarian, prostate, and colorectal cancer: Table 1. <i>Journal of Medical Genetics</i> , 2012, 49, 429-432.	3.2	41
13	<i>CHEK2</i> c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population. <i>BMC Cancer</i> , 2017, 17, 620.	2.6	29
14	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	2.5	28
15	<i>FANCM</i> mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 217-226.	2.5	26
16	<i>RAD51B</i> in Familial Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0153788.	2.5	26
17	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .	0.3	25
18	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	2.8	24

#	ARTICLE	IF	CITATIONS
19	Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 463-469.	2.5	24
20	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	1.3	22
21	RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families. <i>SpringerPlus</i> , 2015, 4, 92.	1.2	21
22	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
23	Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 2692-2700.	5.1	19
24	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
25	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	1.4	15
26	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	6.4	15
27	FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome. <i>International Journal of Cancer</i> , 2016, 139, 2760-2770.	5.1	13
28	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	1.8	13
29	Gene-panel testing of breast and ovarian cancer patients identifies a recurrent <i>RAD51C</i> duplication. <i>Clinical Genetics</i> , 2018, 93, 595-602.	2.0	11
30	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	2.5	9
31	Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients. <i>BMC Cancer</i> , 2012, 12, 552.	2.6	8
32	Screening of HELQ in breast and ovarian cancer families. <i>Familial Cancer</i> , 2016, 15, 19-23.	1.9	7
33	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5